A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With alpha-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan.

Trial Profile

A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With alpha-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Alogliptin (Primary) ; Voglibose
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Dec 2010 New source identified and integrated (ClinicalTrials.gov, NCT01263483).
    • 17 Dec 2010 Actual initiation date (Jan 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top